JP2018537400A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537400A5
JP2018537400A5 JP2018511202A JP2018511202A JP2018537400A5 JP 2018537400 A5 JP2018537400 A5 JP 2018537400A5 JP 2018511202 A JP2018511202 A JP 2018511202A JP 2018511202 A JP2018511202 A JP 2018511202A JP 2018537400 A5 JP2018537400 A5 JP 2018537400A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
nos
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018511202A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537400A (ja
JP7074341B2 (ja
Filing date
Publication date
Priority claimed from GBGB1515572.4A external-priority patent/GB201515572D0/en
Priority claimed from GBGB1612437.2A external-priority patent/GB201612437D0/en
Application filed filed Critical
Priority claimed from PCT/EP2016/070664 external-priority patent/WO2017037203A1/en
Publication of JP2018537400A publication Critical patent/JP2018537400A/ja
Publication of JP2018537400A5 publication Critical patent/JP2018537400A5/ja
Priority to JP2021041608A priority Critical patent/JP2021097706A/ja
Application granted granted Critical
Publication of JP7074341B2 publication Critical patent/JP7074341B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018511202A 2015-09-02 2016-09-01 抗lag-3抗体 Active JP7074341B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021041608A JP2021097706A (ja) 2015-09-02 2021-03-15 抗lag−3抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1515572.4A GB201515572D0 (en) 2015-09-02 2015-09-02 Anti-LAG-3 antibodies
GB1515572.4 2015-09-02
GB1612437.2 2016-07-18
GBGB1612437.2A GB201612437D0 (en) 2016-07-18 2016-07-18 Anti-lag-3 antibodies
PCT/EP2016/070664 WO2017037203A1 (en) 2015-09-02 2016-09-01 Anti-LAG-3 Antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021041608A Division JP2021097706A (ja) 2015-09-02 2021-03-15 抗lag−3抗体

Publications (3)

Publication Number Publication Date
JP2018537400A JP2018537400A (ja) 2018-12-20
JP2018537400A5 true JP2018537400A5 (https=) 2019-10-17
JP7074341B2 JP7074341B2 (ja) 2022-05-24

Family

ID=56852278

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018511202A Active JP7074341B2 (ja) 2015-09-02 2016-09-01 抗lag-3抗体
JP2021041608A Pending JP2021097706A (ja) 2015-09-02 2021-03-15 抗lag−3抗体
JP2022113055A Withdrawn JP2022137218A (ja) 2015-09-02 2022-07-14 抗lag-3抗体
JP2024092967A Pending JP2024116273A (ja) 2015-09-02 2024-06-07 抗lag-3抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021041608A Pending JP2021097706A (ja) 2015-09-02 2021-03-15 抗lag−3抗体
JP2022113055A Withdrawn JP2022137218A (ja) 2015-09-02 2022-07-14 抗lag-3抗体
JP2024092967A Pending JP2024116273A (ja) 2015-09-02 2024-06-07 抗lag-3抗体

Country Status (19)

Country Link
US (2) US11680104B2 (https=)
EP (2) EP3798234A1 (https=)
JP (4) JP7074341B2 (https=)
KR (2) KR20250073532A (https=)
CN (2) CN117510633A (https=)
AU (2) AU2016316730B2 (https=)
CA (1) CA2995639A1 (https=)
DK (1) DK3344654T3 (https=)
ES (1) ES2842306T3 (https=)
IL (1) IL257798B2 (https=)
MX (2) MX2018002610A (https=)
MY (1) MY205096A (https=)
PH (1) PH12018500369A1 (https=)
PL (1) PL3344654T3 (https=)
PT (1) PT3344654T (https=)
RU (2) RU2021133819A (https=)
SG (1) SG10201913864RA (https=)
WO (1) WO2017037203A1 (https=)
ZA (1) ZA201801432B (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
KR20250073532A (ko) * 2015-09-02 2025-05-27 이뮤텝 에스.에이.에스. 항-lag-3 항체
NZ739090A (en) 2015-10-02 2025-06-27 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
SG10201912663YA (en) 2016-10-11 2020-03-30 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
RU2761377C2 (ru) 2017-04-03 2021-12-07 Ф. Хоффманн-Ля Рош Аг Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
TWI690538B (zh) 2017-04-05 2020-04-11 瑞士商赫孚孟拉羅股份公司 特異性結合至pd1至lag3的雙特異性抗體
SI3606954T1 (sl) * 2017-04-05 2022-10-28 F. Hoffmann - La Roche Ag Protitelesa proti LAG3
EP3615572A1 (en) * 2017-04-27 2020-03-04 Tesaro Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
SMT202300418T1 (it) 2017-05-30 2024-01-10 Bristol Myers Squibb Co Trattamento di tumori positivi per lag-3
EP3630179A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
KR20200042937A (ko) * 2017-08-30 2020-04-24 페인스 테라퓨틱스 인코포레이티드 항-lag-3 항체 및 이의 용도
RU2771384C2 (ru) * 2017-12-22 2022-05-04 Цзянсу Хэнжуй Медсин Ко., Лтд. Фармацевтическая композиция, содержащая антитело к lag-3, и ее применение
WO2019129137A1 (zh) * 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
US11661452B2 (en) 2018-03-20 2023-05-30 WuXi Biologics Ireland Limited Anti-lag-3 antibody polypeptide
US20210077477A1 (en) * 2018-03-27 2021-03-18 Raz Yirmiya Microglia modulators for use in treatment of depression
CN110343178B (zh) * 2018-04-03 2022-07-22 上海开拓者生物医药有限公司 抗人lag-3单克隆抗体及其应用
CN110606892B (zh) * 2018-06-14 2023-09-26 华博生物医药技术(上海)有限公司 一种高亲和力高生物活性的lag-3抗体及其应用
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
CN111620949A (zh) * 2019-02-28 2020-09-04 三生国健药业(上海)股份有限公司 结合人lag-3的抗体、其制备方法和用途
GB201906118D0 (en) 2019-05-01 2019-06-12 Immutep S A Anti-LAG-3 binding molecules
GB201906127D0 (en) 2019-05-01 2019-06-12 Immutep S A Assays
SG11202111262XA (en) 2019-05-13 2021-11-29 Regeneron Pharma Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
EP3984554A4 (en) * 2019-06-11 2023-11-08 ONO Pharmaceutical Co., Ltd. IMMUNOSUPPRESSANT
CN115666648A (zh) * 2020-04-03 2023-01-31 索伦托药业有限公司 结合lag3的工程化抗体
US11667711B2 (en) 2020-05-27 2023-06-06 Agilent Technologies, Inc. Anti-human LAG-3 antibodies and their use in immunohistochemistry (IHC)
KR20230050389A (ko) 2020-08-13 2023-04-14 브리스톨-마이어스 스큅 컴퍼니 Il-2를 관심 표적 세포로 재지시하는 방법
WO2022087402A1 (en) 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
CN116514971B (zh) * 2020-12-10 2023-10-27 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
JP2026505276A (ja) 2023-01-31 2026-02-13 ユニバーシティ オブ ロチェスター Staphylococcus aureus感染症を治療するための免疫チェックポイント遮断療法
WO2024192033A1 (en) 2023-03-13 2024-09-19 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma
WO2025106736A2 (en) 2023-11-15 2025-05-22 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
US20250197493A1 (en) 2023-12-13 2025-06-19 Eli Lilly And Company Lag-3 agonist antibodies
WO2025242209A1 (zh) * 2024-05-24 2025-11-27 杭州阿诺生物医药科技有限公司 一种融合多肽及其用途
WO2025247197A1 (zh) * 2024-05-27 2025-12-04 杭州阿诺生物医药科技有限公司 一种多功能融合蛋白
WO2026035866A1 (en) 2024-08-07 2026-02-12 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
EP1637608B1 (en) 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
KR20060099543A (ko) 1994-12-09 2006-09-19 임페리얼 컬리지 이노베이션스 리미티드 유전자의 동정
AU4188196A (en) 1994-12-22 1996-07-10 Nissan Chemical Industries Ltd. Organobismuth derivatives and process for producing the same
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU701375B2 (en) 1995-07-21 1999-01-28 Institut Gustave Roussy Methods for detecting, identifying, isolating, and selectively labelling and targeting Th1 lymphocytes by means of the LAG-3 protein
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
CA2249998A1 (en) 1996-03-27 1997-10-02 Crc For Biopharmaceutical Research Pty. Ltd. The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
TW371617B (en) 1996-10-09 1999-10-11 Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US7259247B1 (en) 1997-09-23 2007-08-21 Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes Anti-human T-cell costimulating polypeptide monoclonal antibodies
AR014621A1 (es) 1997-12-12 2001-03-28 Macromed Inc Un poli (etilenglicol) con forma de estrella, heterofuncional, biocompatible, metodo para su obtencion y metodo para conjugarlo con una proteina
CZ20003099A3 (cs) 1998-02-25 2002-04-17 Lexigen Pharmaceuticals Corporation Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US5985577A (en) 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
FI1897548T4 (fi) * 2003-02-28 2024-09-03 The Johns Hopkins University T-solujen säätely
CN1845938B (zh) 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
AU2005235718B2 (en) 2004-04-23 2011-09-22 Bundesrepublik Deutschland Letztvertreten Durch Das Robert-Koch-Institut Vertreten Durch Seinen Prasidenten Method for the treatment of T cell mediated conditions by depletion of icos-positive cells in vivo
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
JP2008512353A (ja) 2004-07-21 2008-04-24 グライコフィ, インコーポレイテッド 主にGlcNAc2Man3GlcNAc2グリコフォームを含むイムノグロブリン
CN101027100A (zh) 2004-07-22 2007-08-29 健泰科生物技术公司 治疗干燥综合征的方法
JP4997108B2 (ja) 2005-07-22 2012-08-08 協和発酵キリン株式会社 遺伝子組換え抗体組成物
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP1987839A1 (en) * 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US9585957B2 (en) 2007-09-07 2017-03-07 The Johns Hopkins University Adenosine receptor agonists and antagonists to modulate T cell responses
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN102762593B (zh) 2009-07-31 2015-05-20 梅达雷克斯有限责任公司 抗btla的完全人抗体
ES2624835T3 (es) * 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN103249742B (zh) 2010-09-16 2017-04-12 巴利奥医药股份公司 抗人肿瘤坏死因子1型受体抗体
EP2742953B1 (en) 2011-08-11 2021-09-22 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EA037554B1 (ru) * 2013-03-15 2021-04-13 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Анти-lag-3 связывающие белки
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
KR20250073532A (ko) * 2015-09-02 2025-05-27 이뮤텝 에스.에이.에스. 항-lag-3 항체

Similar Documents

Publication Publication Date Title
JP2018537400A5 (https=)
RU2021133819A (ru) Анти-lag-3 антитела
JP7144477B2 (ja) 抗pd-l1抗体
JP6986965B2 (ja) 抗pd−1抗体
TWI489996B (zh) Cd127結合蛋白質
CN109651507B (zh) 一种激动型4-1bb单克隆抗体
JP6976322B2 (ja) 新規抗ctla4抗体
CN113454119B (zh) 抗btla抗体
RU2011145428A (ru) АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
JP2012526558A5 (https=)
AU2017240150A1 (en) BCMA binding molecules and methods of use thereof
JP2020502996A5 (https=)
AU2016313404A1 (en) PD-L1 ("programmed death-ligand 1") antibodies
JP2020505386A5 (https=)
JP2012500020A5 (https=)
JP2019522961A5 (https=)
CN106795219A (zh) 抗il‑17抗体及其生产和使用的方法
CN103946238A (zh) 抗ox40抗体及使用其的方法
EA035112B1 (ru) Биспецифическое антитело, которое связывается с ох40 человека и сывороточным альбумином человека, его получение и применение
FI3525583T3 (fi) Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
RU2022108410A (ru) Терапевтические антитела против лиганда cd40
CN116789820A (zh) 一种新型免疫调节剂的开发和应用
JP2021509274A (ja) モノクローナル抗体およびその使用法
JP2021530511A5 (https=)
FI4157876T3 (fi) Anti-pd-1 -vasta-aineita